PDL BioPharma
| Public | |
| Traded as | NASDAQ: PDLI |
| Industry | Biotechnology |
Key people |
John McLaughlin (CEO) |
| Revenue | $590.4 million (2015)[1] |
| Website |
pdl |
PDL BioPharma (known as Protein Design Labs prior to 2006) is a publicly traded American shell company that since 2008 manages patents and other intellectual property that had been generated by the company.[2][3] In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million.[4][5]
Protein Design Labs had been founded in 1986[5] and was a pioneer in humanizing monoclonal antibodies. Its humanization technology was used in several monoclonal antibody drugs under licensing and collaboration agreements; such products included rituximab (Rituxan), bevacizumab (Avastin), and palivizumab (Synagis).[6] It held its initial public offering in 1992[7] and by 1994 it had 13 compounds in its pipeline, and had partnered its lead product, the humanized monoclonal antibody daclizumab, with Roche under a license that called for a 15% royalty.[8] Daclizumab became the first humanized monoclonal antibody approved for human use in 1997.[9] PDL made another public offering in 2000, at the peak of the biotech IPO window that ran from 1998 to 2001.[6][10] In 2003 it settled litigation with Genentech over royalty payments owed to PDL under their license agreement; annual royalties were anticipated at that time to be around $90M per year.[11] These are the kinds of intellectual property and license agreements that PDL manages on behalf of its shareholders since 2008;[3] in 2007 those royalty payments were around $220 million.[5]
One of the development programs that PDL had transferred to Facet was the use of daclizumab in indications it had never licensed to Roche, including multiple sclerosis. Facet partnered that development program with Biogen Idec which attempted a hostile buy out of Facet for $350M in 2009;[12] Facet rejected that offer and was purchased by Abbvie for $450 million in cash the next year.[13] The FDA approved daclizumab for multiple sclerosis in 2016 under the trade name Zinbryta.[14]
References
- ↑ "PDL BioPharma Announces Fourth Quarter and Full Year 2015 Financial Results (NASDAQ:PDLI)".
- ↑ Bloomberg company profile Page accessed May 31, 2016
- 1 2 Peter Kolchinsky for In Vivo. July/August 2011 How To Create A Lasting Peace Between Biotech Management, Shareholders And Employees
- ↑ John Carroll for FierceBiotech. 2009 Emerging Drug Developer: Facet Biotech
- 1 2 3 PDL BioPharma, Inc. Form 8-K December 17, 2008
- 1 2 Thiel KA. A very firm handshake: biotech's growing negotiating power. Nat Biotechnol. 2005 Oct;23(10):1221-6. PMID 16211058
- ↑ Staff, New York Times. January 30, 1992 Finance Briefs
- ↑ The Pharma Letter. July 25, 1994 Protein Design: Rising Star In A Depressed sector?
- ↑ Lawrence M. Fisher for The New York Times. December 12, 1997 Genetically Engineered Drug Approved for Kidney Transplants
- ↑ Wiechers IR, Perin NC, Cook-Deegan R. The emergence of commercial genomics: analysis of the rise of a biotechnology subsector during the Human Genome Project, 1990 to 2004. Genome Med. 2013 Sep 20;5(9):83. PMID 24050173 PMC 3971346
- ↑ Times Wire Services in the Los Angeles Times. December 02, 2003 Genentech to Pay Royalties in Patent Dispute
- ↑ Luke Timmerman for Xconomy. September 4, 2009 Biogen Idec Makes Hostile $350M Takeover Bid for Facet Biotech
- ↑ Staff, New York Times Dealbook. March 9, 2010. Abbott to Buy Facet Biotech for 67% Premium
- ↑ FDA News Release: FDA approves Zinbryta to treat multiple sclerosis May 27, 2016